NCT05059912View on ClinicalTrials.gov

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

August 3, 2023

Study Completion Date

August 3, 2024

Conditions
Refractory and Relapsed T Cell Lymphoma
Interventions
BIOLOGICAL

Humanized CD7 CAR-T cells

Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
collaborator

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

Affiliated Hospital of Jiangnan University

OTHER

collaborator

Affiliated Zhongshan Hospital of Dalian University

OTHER

collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER